首页> 外文OA文献 >Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

【2h】

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

机译：来那度胺在5q缺失的中度2或高危骨髓增生异常综合征中的疗效和安全性：2期研究的结果。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Adès Lionel; Boehrer S; Prebet Thomas; Beyne-Rauzy Odile; Legros Laurence; Ravoet Christophe; Dreyfus François; Stamatoullas Aspasia; Chaury Marie Pierre; Delaunay Jacques; Laurent Gauthier; Vey Norbert; Burcheri Sara; Mbida Rose-Marie; Hoarau Natacha; Gardin C; Fenaux Pierre;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. [J] . Ades L, Boehrer S, Prebet T, Blood: The Journal of the American Society of Hematology . 2009,第17期

机译：来那度胺在5q缺失的中度2或高危骨髓增生异常综合征中的疗效和安全性：2期研究的结果。
2. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion [J] . Vu H. Duong, Rami S. Komrokji, Alan F. List Therapeutic advances in hematology. . 2012,第2期

机译：来那度胺对5q染色体缺失的骨髓增生异常综合征患者的疗效和安全性
3. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion [J] . Vu H. Duong, Rami S. Komrokji, Alan F. List Therapeutic advances in hematology. . 2012,第2期

机译：来那度胺对5q染色体缺失的骨髓增生异常综合征患者的疗效和安全性
4. Efficacy and Safety of a Porcine Collagen Sponge for Cranial Neurosurgery: A Prospective Case-Control Study. [C] . Brao R.A., Costa B.S., Carvalho G.T., EANS Annual Meeting . 2013

机译：猪胶原海绵颅神经外科海绵的功效和安全性：一项潜在病例对照研究。
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM) [O] . Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, 2019

机译：氮杂胞苷强化治疗方案在中度和高风险的骨髓增生异常综合症患者中进行二期临床研究的有效性和安全性：Groupe Francophone des Myelodysplasies（GFM）进行的一项研究
7. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis. [O] . Xin-Yue Lian, Zhi-Hui Zhang, Zhao-Qun Deng, 2016

机译：来那度胺治疗低或中度1风险骨髓增生异常综合征的有效性和安全性，有或没有5q缺失：系统评价和meta分析。
8. Role of mDia1 in the Aberrant Innate Immune Signaling in del(5q) Myelodysplastic Syndromes. [R] . Ji, P. 2017

机译：mDia1在del（5q）骨髓增生异常综合征中的异常先天免疫信号中的作用。

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

著录项

引文网络

相似文献

相关主题

期刊订阅